

Raffaele Addeo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2011093/publications.pdf>

Version: 2024-02-01

77
papers

2,414
citations

218677

26
h-index

214800

47
g-index

83
all docs

83
docs citations

83
times ranked

4033
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. <i>Oncologist</i> , 2010, 15, 85-92.	3.7	162
2	Receptor Activator of NF- κ B (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. <i>PLoS ONE</i> , 2011, 6, e19234.	2.5	157
3	Estrogens and Progesterone Promote Persistent CCND1 Gene Activation during G 1 by Inducing Transcriptional Derepression via c- Jun /c- Fos /Estrogen Receptor (Progesterone Receptor) Complex Assembly to a Distal Regulatory Element and Recruitment of Cyclin D1 to Its Own Gene Promoter. <i>Molecular and Cellular Biology</i> . 2004, 24, 7260-7274.	2.3	154
4	Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. <i>Journal of Clinical Oncology</i> , 2010, 28, 543-548.	1.6	142
5	MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e233.	5.1	122
6	Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. <i>Scientific Reports</i> , 2015, 5, 18670.	3.3	95
7	Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. <i>Cancer</i> , 2008, 113, 2524-2531.	4.1	88
8	Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 301-306.	2.4	84
9	Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 469-475.	3.4	82
10	Estrogen Induces Early and Timed Activation of Cyclin-Dependent Kinases 4, 5, and 6 and Increases Cyclin Messenger Ribonucleic Acid Expression in Rat Uterus. <i>Endocrinology</i> , 1997, 138, 978-984.	2.8	78
11	Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 837-844.	2.3	73
12	Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life. <i>BMC Cancer</i> , 2007, 7, 18.	2.6	72
13	Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 34-39.	2.3	66
14	A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 417-424.	2.9	60
15	Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. <i>Supportive Care in Cancer</i> , 2013, 21, 1313-1319.	2.2	57
16	The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. <i>Expert Review of Hematology</i> , 2013, 6, 587-597.	2.2	52
17	Zoledronic acid: an unending tale for an antiresorptive agent. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 141-154.	1.8	50
18	Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. <i>Future Oncology</i> , 2016, 12, 373-387.	2.4	43

#	ARTICLE	IF	CITATIONS
19	Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women ≥65 years of age. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 285-292.	2.3	39
20	Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. <i>Cancer Biology and Therapy</i> , 2011, 12, 112-118.	3.4	37
21	Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients. <i>Cancer Biology and Therapy</i> , 2010, 9, 685-693.	3.4	34
22	Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 603-609.	2.3	34
23	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33
24	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014, 12, 291.	4.4	32
25	Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series. <i>Oncology</i> , 2013, 84, 265-272.	1.9	27
26	Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?. <i>World Journal of Gastroenterology</i> , 2016, 22, 6114.	3.3	27
27	Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1137-1143.	2.3	26
28	The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion. <i>Molecular and Cellular Endocrinology</i> , 2000, 165, 199-209.	3.2	21
29	A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 199-201.	2.4	21
30	Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 499-505.	2.4	20
31	Atrial fibrillation following chemotherapy for stage III diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease). <i>Annals of Hematology</i> , 2005, 84, 192-193.	1.8	18
32	Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. <i>Supportive Care in Cancer</i> , 2008, 16, 209-214.	2.2	18
33	Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. <i>Future Oncology</i> , 2017, 13, 415-423.	2.4	18
34	Erlotinib: early clinical development in brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1027-1037.	4.1	17
35	The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsons: from rash mitigation to the increase in anti-tumor activity. <i>Current Medical Research and Opinion</i> , 2016, 32, 1839-1848.	1.9	16
36	Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 945-949.	3.1	15

#	ARTICLE	IF	CITATIONS
37	Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opinion on Drug Safety, 2013, 12, 729-740.	2.4	15
38	Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas. Molecular and Clinical Oncology, 2016, 4, 467-471.	1.0	15
39	Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncology Letters, 2019, 18, 3873-3879.	1.8	15
40	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. Frontiers in Oncology, 2019, 9, 1102.	2.8	15
41	Interleukin-2 and Lanreotide in the Treatment of Medullary Thyroid Cancer: In Vitro and In Vivo Studies. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1567-E1574.	3.6	14
42	Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?. Expert Opinion on Investigational Drugs, 2011, 20, 881-895.	4.1	13
43	Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. Expert Opinion on Biological Therapy, 2016, 16, 1075-1078.	3.1	13
44	Conditions Suggesting Lymphoma. Journal of Clinical Oncology, 2005, 23, 3844-3846.	1.6	12
45	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy). Tj ETQq1 1 07843141rgBT /O		
46	Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem. Cancers, 2022, 14, 1716.	3.7	12
47	Glucocorticoids induce G1 Arrest of Lymphoblastic Cells through Retinoblastoma Protein Rb1 Dephosphorylation in Childhood Acute Lymphoblastic Leukemia In Vivo. Cancer Biology and Therapy, 2004, 3, 470-476.	3.4	11
48	The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?. Expert Review of Anticancer Therapy, 2011, 11, 139-142.	2.4	11
49	CheckMate 141 trial: all that glitters is not gold. Expert Opinion on Biological Therapy, 2019, 19, 169-171.	3.1	11
50	Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer Chemotherapy and Pharmacology, 2009, 64, 863-866.	2.3	9
51	Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors. Oncology Reports, 2007, , .	2.6	8
52	Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. Journal of Experimental and Clinical Cancer Research, 2009, 28, 7.	8.6	8
53	Latest developments in targeted therapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1635-1646.	2.4	8
54	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1283-1288.	2.4	8

#	ARTICLE	IF	CITATIONS
55	Locally advanced paranasal sinus carcinoma: A study of 30 patients. <i>Oncology Letters</i> , 2017, 13, 1338-1342.	1.8	8
56	Adenoid cystic carcinoma of the larynx in a 70-year-old patient: A case report. <i>Oncology Letters</i> , 2018, 16, 2783-2788.	1.8	8
57	Acceptance and Adherence of Oral Endocrine Therapy in Women with Metastatic Breast Cancer: Exacampania Group Study. <i>Breast Journal</i> , 2015, 21, 326-328.	1.0	7
58	High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 39.	8.6	6
59	Two faces for Janus: recombinant human erythropoiesis-stimulating agents and cancer mortality. <i>Expert Review of Hematology</i> , 2009, 2, 513-515.	2.2	6
60	Humerus Metastasis From Cholangiocarcinoma: A Case Report. <i>Gastroenterology Research</i> , 2013, 6, 39-41.	1.3	6
61	Squamous cell carcinoma of the tongue in a female with advanced breast cancer: A case report of an elderly patient presenting with two types of cancer. <i>Oncology Letters</i> , 2014, 8, 235-237.	1.8	6
62	Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. <i>Oncology</i> , 2018, 95, 353-359.	1.9	6
63	Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 56-62.	0.5	5
64	Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study. <i>Chemotherapy</i> , 2019, 64, 48-56.	1.6	5
65	Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. <i>CNS Oncology</i> , 2019, 8, CNS32.	3.0	5
66	Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature—A New Goal for Early Diagnosis and Therapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2019.	2.4	5
67	Atypical Cutaneous Lymphoid Hyperplasia Induced by Chemotherapy in a Patient with Advanced Colon Carcinoma. <i>Clinical Colorectal Cancer</i> , 2007, 6, 728-730.	2.3	4
68	Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. <i>Oncology Reports</i> , 2011, 25, 1545-8.	2.6	4
69	ASCO 2013: bevacizumab and glioblastoma—a marriage dissolution?. <i>Current Medical Research and Opinion</i> , 2014, 30, 1871-1873.	1.9	4
70	The best partner for radiotherapy after induction chemotherapy in a larynx preservation strategy. <i>Oral Oncology</i> , 2014, 50, e1-e2.	1.5	3
71	MUC2 a new key for pancreas cancer prognosis. <i>Cancer Biology and Therapy</i> , 2009, 8, 1000-1001.	3.4	1
72	Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?. <i>Expert Review of Hematology</i> , 2014, 7, 517-519.	2.2	1

#	ARTICLE	IF	CITATIONS
73	Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer. High-Throughput, 2020, 9, 4.	4.4	1
74	Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer. Journal of Experimental Pharmacology, 2021, Volume 13, 901-903.	3.2	1
75	Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients. Oncology Reports, 0, , .	2.6	1
76	Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey. Future Oncology, 2014, 10, 69-78.	2.4	0
77	Sarcomatoid larynx carcinoma differential clinical evolution, on field statistical considerations. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, 42, 102934.	1.3	0